We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
NOT ENOUGH BENEFITS SEEN IN POZEN'S MIGRAINE CANDIDATE, SAY FDA EXPERTS.
- Abstract
Reports that the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously on August 4, 2005, that the benefits of Pozen Inc.'s MT100 migraine drug do not outweigh its risks, particularly in the movement disorder known as tardive dyskinesia. Components of the drug; Pozen's announcement on August 5, 2005, that it is discontinuing development of MT 100 in the United States due to the committee's findings.
- Subjects
MIGRAINE; HEADACHE treatment; DRUG side effects; UNITED States. Food &; Drug Administration; POZEN Inc.; TARDIVE dyskinesia
- Publication
Applied Clinical Trials, 2005, Vol 14, Issue 9, p21
- ISSN
1064-8542
- Publication type
Article